PMID- 36891552 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230310 IS - 2666-7762 (Electronic) IS - 2666-7762 (Linking) VI - 28 DP - 2023 May TI - Epidemiology and diagnostic trends of congenital adrenal hyperplasia in Denmark: a retrospective, population-based study. PG - 100598 LID - 10.1016/j.lanepe.2023.100598 [doi] LID - 100598 AB - BACKGROUND: The prevalence of newborns with congenital adrenal hyperplasia (CAH) detected by neonatal screening is well-described, but data including patients diagnosed later in life are extremely limited. This study aimed to describe diagnostic trends for all patients with CAH in Denmark. METHODS: A nationwide population-based registry study including medical record review. FINDINGS: We identified 462 patients (290 females) with any form of CAH. The prevalence of CAH combined was 15.1 (95% confidence interval [CI]: 12.3-16.1) and 9.0 (CI: 7.6-10.4) per 100,000 newborn females and males. There was a prevalence of salt-wasting (SW), simple-virilizing (SV), and non-classic (NC) CAH due to 21-hydroxylase deficiency of: SW-CAH: 6.4 (CI: 5.3-7.6) and 5.6 (CI: 4.6-6.8); SV-CAH: 2.0 (CI: 1.4-2.8) and 1.6 (CI: 1.0-2.7); and NC-CAH: 5.5 (CI: 4.4-6.9) and 2.5 (CI: 1.7-3.7) per 100,000 newborn females and males, respectively. Diagnosis of NC-CAH increased significantly during the course of the study. There was a female preponderance for SV-CAH (ratio: 1.8) and NC-CAH (ratio: 3.2). Median age at diagnosis, females and males respectively: SW-CAH: 4 (interquartile range [IQR]: 0-11) and 14 (IQR: 8-24) days, SV-CAH: 3.1 (IQR: 1.2-6.6) and 4.8 (IQR: 3.2-6.9) years, and NC-CAH: 15.5 (IQR: 7.9-22.5) and 9.4 (IQR: 7.2-23.2) years. INTERPRETATION: The combined prevalence of CAH was 15.1 and 9.0 per 100,000 newborn females and males, respectively. The female preponderance was primarily due to diagnosis of more females than males with NC-CAH. FUNDING: International Fund of Congenital Adrenal Hyperplasia, Health Research Fund of Central Denmark Region, Aase and Einar Danielsen Fund, and "Fonden til Laegevidenskabens Fremme". CI - (c) 2023 The Authors. FAU - Berglund, Agnethe AU - Berglund A AD - Department of Clinical Genetics, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. AD - Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. FAU - Ornstrup, Marie J AU - Ornstrup MJ AD - Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. AD - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. FAU - Lind-Holst, Marie AU - Lind-Holst M AD - Department of Pediatrics, Hans Christian Andersen Children's Hospital, Odense University Hospital, Klovervaenget 23C, 5000, Odense C, Denmark. FAU - Duno, Morten AU - Duno M AD - Department of Clinical Genetics, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Denmark. FAU - Baekvad-Hansen, Marie AU - Baekvad-Hansen M AD - Danish Center for Neonatal Screening, Department for Congenital Disorders, State Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark. FAU - Juul, Anders AU - Juul A AD - Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Copenhagen, Denmark. AD - Research Center EDMaRC, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Copenhagen, Denmark. AD - Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Denmark. FAU - Borch, Luise AU - Borch L AD - Department of Pediatrics, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. AD - Department of Pediatrics and Adolescent Medicine, NIDO, Godstrup Hospital, Hospitalsparken 15, 7400, Herning, Denmark. FAU - Jorgensen, Niels AU - Jorgensen N AD - Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Copenhagen, Denmark. AD - Research Center EDMaRC, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Copenhagen, Denmark. FAU - Rasmussen, Ase K AU - Rasmussen AK AD - Department of Endocrinology and Metabolism, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Denmark. FAU - Andersen, Marianne AU - Andersen M AD - Department of Endocrinology, Odense University Hospital, J. B. Winslows Vej 4, 5000, Odense C, Denmark. FAU - Main, Katharina M AU - Main KM AD - Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Copenhagen, Denmark. AD - Research Center EDMaRC, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen O, Copenhagen, Denmark. AD - Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Denmark. FAU - Hansen, Dorte AU - Hansen D AD - Department of Pediatrics, Hans Christian Andersen Children's Hospital, Odense University Hospital, Klovervaenget 23C, 5000, Odense C, Denmark. FAU - Gravholt, Claus H AU - Gravholt CH AD - Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. AD - Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. AD - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. LA - eng PT - Journal Article DEP - 20230228 PL - England TA - Lancet Reg Health Eur JT - The Lancet regional health. Europe JID - 101777707 PMC - PMC9986638 OTO - NOTNLM OT - Congenital adrenal hyperplasia OT - Diagnosis age OT - Epidemiology OT - Incidence OT - Prevalence COIS- M Dunoe reports honoria for post graduate lectures in medical genetics. A Juul reports honoria from Novo Nordisk A/S, Ipsen, and Sandoz. KM Main reports grants from the Novo Nordisk Foundation, the Innovation Fund, and the Capital Region Research Fund; Royalties from Gyldendal; Consulting fees from The National Board of Wealth and Welfare, Sweden; lectures for Novo Nordisk A/S; and payment for medical expert testimony for The Ministry of Justice, Department of Civil Affairs. The remaining authors have nothing to disclose. EDAT- 2023/03/10 06:00 MHDA- 2023/03/10 06:01 PMCR- 2023/02/28 CRDT- 2023/03/09 02:17 PHST- 2022/11/04 00:00 [received] PHST- 2023/02/06 00:00 [revised] PHST- 2023/02/06 00:00 [accepted] PHST- 2023/03/09 02:17 [entrez] PHST- 2023/03/10 06:00 [pubmed] PHST- 2023/03/10 06:01 [medline] PHST- 2023/02/28 00:00 [pmc-release] AID - S2666-7762(23)00016-9 [pii] AID - 100598 [pii] AID - 10.1016/j.lanepe.2023.100598 [doi] PST - epublish SO - Lancet Reg Health Eur. 2023 Feb 28;28:100598. doi: 10.1016/j.lanepe.2023.100598. eCollection 2023 May.